Pharmaceutical Tablets: A Complete Guide to IPQC Testing

Evaluate tablet appearance and dimensions to ensure quality, consistency, and patient acceptance, guiding color, shape, size, surface defects, thickness, and diameter against pharmacopoeial standards.

Assess weight variation test to ensure tablet uniformity and accurate dosing by evaluating 20 tablets against pharmacopeial tolerances and common causes.

Assess tablet hardness to ensure durability for handling and transport while maintaining disintegration, using Monsanto and Pfizer testers with ten-sample average against 4–8 kg/cm square and 12 kg/cm square (coated).

Perform friability testing to assess tablet durability against handling, packaging, and transportation, measuring initial and final weights to ensure no more than 1% weight loss, with retest and process controls.

Perform the disintegration test for tablets using a six-tube basket, a 1-liter beaker, and a 37°C medium at 29–32 cycles to verify pharmacopoeial limits for uncoated, film-coated, and enteric tablets.

Identify common disintegration test issues, including failure to disintegrate, uneven disintegration, screen clogging, and temperature fluctuations; apply fixes by adjusting formulation, disintegrant level, coating, cleanliness, and temperature control.

Learn how the dissolution test assesses tablet drug release using basket or paddle methods, proper media and sink conditions, and spectrophotometry or high-performance liquid chromatography (hplc) to ensure quality control.

Identify common dissolution test issues—inconsistent results from improper calibration or tablet variation, poor dissolution from incorrect medium or sync conditions, and foaming from surfactants—by calibrating apparatus, standardizing batches, and degassing.

Assess how content uniformity testing ensures every tablet delivers the correct API dose, meets pharmacopoeial limits, and supports regulatory compliance, therapeutic efficacy, and patient safety.

Investigate friability failure in tablet manufacturing. Identify root causes—insufficient binder, overdried granules, and inadequate compression—and apply corrective actions to meet pharmacopoeial limits, with regular in-process checks.

A case study analyzes dissolution failure, identifying solubility, coating thickness, and dissolution medium issues, then applies solid dispersion, thinner coating, and appropriate medium to achieve over 80% release.